Gaucher disease and malignancy: A model for cancer pathogenesis in an inborn error of metabolism

Critical Reviews in Oncogenesis

Volumn 18, Issue 3, 2013, Pages 235-246

  Mistry, Pramod K ^a   Taddei, Tamar ^a   vom Dahl, Stephan ^b   Rosenbloom, Barry E ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b St Franziskus Hospital Koln   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer risk; Enzyme replacement therapy; Gaucher disease; Glucocerebroside; Modifier genes; Multiple cancers; Multiple myeloma; Substrate reduction therapy

Indexed keywords

ALGLUCERASE; GLUCOSYLCERAMIDE; IMIGLUCERASE;

ARTICLE; CANCER PATIENT; CANCER RISK; CELL ACTIVATION; CELL STIMULATION; CHRONIC INFLAMMATION; DNA MODIFICATION; ENDOPLASMIC RETICULUM STRESS; ENZYME REPLACEMENT; GAUCHER DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERFERRITINEMIA; IMMUNE DYSREGULATION; INCIDENCE; MACROPHAGE; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; PATHOGENESIS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; SPLENECTOMY; T LYMPHOCYTE;

ANIMALS; GAUCHER DISEASE; HUMANS; NEOPLASMS;

EID: 84875283093     PISSN: 08939675     EISSN: 21626448     Source Type: Journal    
DOI: 10.1615/CritRevOncog.2013006145     Document Type: Article

References (69)

1. Erez A, Shchelochkov OA, Plon SE, Scaglia F, Lee B. Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism. Am J Hum Gen. 2011;88:402-21.
2. Hughes D, Cappellini MD, Berger M, Van Droogenbroeck J, de Fost M, Janic D, Marinakis T, Rosenbaum H, Villarubia J, Zhukovskaya E, Hollak C. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Brit J Haematol. 2007;138:676-86.
3. Sidransky E. Gaucher disease: complexity in a "simple" disorder. Mole Gen Metab. 2004;83:6-15.
4. Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet. 2008;372:1263-71.
5. Lo SM, Liu J, Chen F, Pastores GM, Knowles J, Boxer M, Aleck K, Mistry PK. Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapy. J Inher Metab Dis. 2011;34:643-50.
6. Harats D, Pauzner R, Elstein D, Many A, Klutstein MW, Kramer MR, Farfel Z, Zimran A. Pulmonary hypertension in two patients with type I Gaucher disease while on alglucerase therapy. Acta Haematol. 1997;98(1):47-50.
7. Bultron G, Kacena K, Pearson D, Boxer M, Yang R, Sathe S, Pastores G, Mistry PK. The risk of Parkinson's disease in type 1 Gaucher disease. J Inher Metab Dis. 2010;33:167-73.
8. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E. Parkinsonism among Gaucher disease carriers. J Med Gen. 2004;41:937-40.
9. Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, Aghai E, Reches A, Bembi B, Zimran A. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM. 1996;89(9):691-4.
10. Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D. Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cell Mol Dis. 2005;34:197-200.
11. de Fost M, Vom Dahl S, Weverling GJ, Brill N, Brett S, Haussinger D, Hollak CE. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cell Mol Dis. 2006;36:53-8.
12. Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood. 2005;105:4569-72.
13. Taddei TH, Kacena KA, Yang M, Yang R, Malhotra A, Boxer M, Aleck KA, Rennert G, Pastores GM, Mistry PK. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol. 2009;84:208-14.
14. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE, Grewal RP, Yu K. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. NEJM. 1991;324:1464-1470.
15. Cox TM. Gaucher disease: clinical profile and therapeutic developments. Biologics: Targets & Therapy. 2010;4:299-313.
16. Grabowski GA. Treatment perspectives for the lysosomal storage diseases. Expert Opin Emerging Drugs. 2008;13:197-211.
17. Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 2007;82:697-701.
18. Desnick RJ. Gaucher disease: a century of delineation and understanding. Prog Clin Biol Res. 1982;95:1-30.
19. Pins MR, Mankin HJ, Xavier RJ, Rosenthal DI, Dickersin GR, Rosenberg AE. Malignant epithelioid hemangioendothelioma of the tibia associated with a bone infarct in a patient who had Gaucher disease. A case report. J Bone Joint Surg Am. 1995;77:777-81.
20. Erjavec Z, Hollak CE, de Vries EG. Hepatocellular carcinoma in a patient with Gaucher disease on enzyme supplementation therapy. Ann Oncol ESMO. 1999;10:243.
21. Taddei T, Mistry P, Schilsky ML. Inherited metabolic disease of the liver. Curr Opin Gastroenterol. 2008;24:278-86.
22. Xu R, Mistry P, McKenna G, Emre S, Schiano T, Bu-Ghanim M, Levi G, Fiel MI. Hepatocellular carcinoma in type 1 Gaucher disease: a case report with review of the literature. Sem Liver Dis. 2005;25:226-9.
23. Lee RE. The pathology of Gaucher disease. Prog Clin Biol Res. 1982;95:177-217.
24. Shiran A, Brenner B, Laor A, Tatarsky I. Increased risk of cancer in patients with Gaucher disease. Cancer. 1993;72:219-24.
25. Lo SM, Stein P, Mullaly S, Bar M, Jain D, Pastores GM, Mistry PK. Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types-correlation with genotype and phenotype. Am J Hematol. 2010;85:340-5.
26. Webb BD, Weinreb NJ, Botti AC, Kirmse BM, Balwani M. JAK2V617F mutation and myeloproliferative malignancy in a patient with Type 1 Gaucher disease. Blood Cell MolDis. 2011;46:103-4.
27. Landgren O, Turesson I, Gridley G, Caporaso NE. Risk of malignant disease among 1525 adult male US Veterans with Gaucher disease. Arch Intern Med. 2007;167:1189-94.
28. Weinreb NJ, Andersson HC, Banikazemi M, Barranger J, Beutler E, Charrow J, Grabowski GA, Hollak CE, Kaplan P, Mankin H, Mistry PK, Rosenbloom BE, Vom Dahl S, Zimran A. Prevalence of type 1 Gaucher disease in the United States. Arch Intern Med. 2008;168:326-8.
29. Hein LK, Duplock S, Hopwood JJ, Fuller M. Lipid composition of microdomains is altered in a cell model of Gaucher disease. J Lipid Res. 2008;49:1725-34.
30. Dekker N, van Dussen L, Hollak CE, Overkleeft H, Scheij S, Ghauharali K, van Breemen MJ, Ferraz MJ, Groener JE, Maas M, Wijburg FA, Speijer D, Tylki-Szymanska A, Mistry PK, Boot RG, Aerts JM. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood. 2011;118:e118-27.
31. Boot RG, Verhoek M, Donker-Koopman W, Strijland A, van Marle J, Overkleeft HS, Wennekes T, Aerts JM. Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2. The J Biol Chem. 2007;282:1305-12.
32. Mistry PK, Liu J, Yang M, Nottoli T, McGrath J, Jain D, Zhang K, Keutzer J, Chuang WL, Mehal WZ, Zhao H, Lin A, Mane S, Liu X, Peng YZ, Li JH, Agrawal M, Zhu LL, Blair HC, Robinson LJ, Iqbal J, Sun L, Zaidi M. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Nat Acad Sci U S A. 2010;107:19473-8.
33. Liu J, Halene S, Yang M, Iqbal J, Yang R, Mehal WZ, Chuang WL, Jain D, Yuen T, Sun L, Zaidi M, Mistry PK Gaucher disease gene GBA functions in immune regulation. Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):10018-23.
34. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nature Rev Mole Cell Biol. 2008;9:139-50.
35. Hulkova H, Ledvinova J, Poupetova H, Kohout A, Malinova V, Elleder M. Autopsy case of Gaucher disease type I in a patient on enzyme replacement therapy. Comments on the dynamics of persistent storage process. J Inher Metab Dis. 2009;32:551-9.
36. Taddei TH, Dziura J, Chen S, Yang R, Hyogo H, Sullards C, Cohen DE, Pastores G, Mistry PK. High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease. J Inher Metab Dis. 2010;33:291-300.
37. Boven LA, van Meurs M, Boot RG, Mehta A, Boon L, Aerts JM, Laman JD. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol. 2004;122:359-69.
38. Boot RG, Verhoek M, de Fost M, Hollak CE, Maas M, Bleijlevens B, van Breemen MJ, van Meurs M, Boven LA, Laman JD, Moran MT, Cox TM, Aerts JM. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood. 2004;103:33-9.
39. Bussink AP, van Eijk M, Renkema GH, Aerts JM, Boot RG. The biology of the Gaucher cell: the cradle of human chitinases. Int Rev Cytology. 2006;252:71-128.
40. Deegan PB, Moran MT, McFarlane I, Schofield JP, Boot RG, Aerts JM, Cox TM. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cell Mole Dis. 2005;35:259-67.
41. Marti GE, Ryan ET, Papadopoulos NM, Filling-Katz M, Barton N, Fleischer TA, Rick M, Gralnick HR. Polyclonal B-cell lymphocytosis and hypergammaglobulinemia in patients with Gaucher disease. Am J Hematol. 1988;29:189-94.
42. de Fost M, Out TA, de Wilde FA, Tjin EP, Pals ST, van Oers MH, Boot RG, Aerts JF, Maas M, Vom Dahl S, Hollak CE. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol. 2008;87:439-49.
43. Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. QJM: Mon J Assoc Physician. 1997;90:19-25.
44. Barak V, Acker M, Nisman B, Kalickman I, Abrahamov A, Zimran A, Yatziv S. Cytokines in Gaucher's disease. Eur Cytokine Net. 1999;10:205-10.
45. Michelakakis H, Spanou C, Kondyli A, Dimitriou E, Van Weely S, Hollak CE, Van Oers MH, Aerts JM. Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease. Biochim Biophys Acta. 1997;1317(3):219-22.
46. Mizukami H, Mi Y, Wada R, Kono M, Yamashita T, Liu Y, Werth N, Sandhoff R, Sandhoff K, Proia RL. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. J Clin Invest. 2002;109(9):1215-21.
47. Lacerda L, Arosa FA, Lacerda R, Cabeda J, Porto G, Amaral O, Fortuna A, Pinto R, Oliveira P, McLaren CE, Sá Miranda C, de Sousa M. T cell numbers relate to bone involvement in Gaucher disease. Blood Cell Mole Dis. 1999;25:130-8.
48. Balreira A, Cavallari M, Sa Miranda MC, Arosa FA. Uncoupling between CD1d upregulation induced by retinoic acid and conduritol-B-epoxide and iNKT cell responsiveness. Immunobiology. 2010;215:505-13.
49. Micheva I, Marinakis T, Repa C, Kouraklis-Symeonidis A, Vlacha V, Anagnostopoulos N, Zoumbos N, Symeonidis A. Dendritic cells in patients with type I Gaucher disease are decreased in number but functionally normal. Blood Cell Mole Dis. 2006;36:298-307.
50. Bassan R, Montanelli A, Barbui T. Interaction between a serum factor and T lymphocytes in Gaucher disease. Am J Hematol. 1985;18:381-4.
51. Stein P, Yu H, Jain D, Mistry PK. Hyperferritinemia and iron overload in type 1 Gaucher disease. Am J Hematol. 2010;85:472-6.
52. Koprivica V, Stone DL, Park JK, Callahan M, Frisch A, Cohen IJ, Tayebi N, Sidransky E. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Human Gen. 2000;66:1777-86.
53. Amato D, Stachiw T, Clarke JT, Rivard GE. Gaucher disease: variability in phenotype among siblings. J Inher Metab Dis. 2004;27:659-69.
54. Biegstraaten M, van Schaik IN, Aerts JM, Langeveld M, Mannens MM, Bour LJ, Sidransky E, Tayebi N, Fitzgibbon E, Hollak CE. A monozygotic twin pair with highly discordant Gaucher phenotypes. Blood Cell Mole Dis. 2011;46:39-41.
55. Lachmann RH, Grant IR, Halsall D, Cox TM. Twin pairs showing discordance of phenotype in adult Gaucher's disease. QJM: Mon J Assoc Physician. 2004;97:199-204.
56. Beutler E. Gaucher disease as a paradigm of current issues regarding single gene mutations of humans. Proc Nat Acad Sci U S A. 1993;90:5384-90.
57. Lu J, Chiang J, Iyer RR, Thompson E, Kaneski CR, Xu DS, Yang C, Chen M, Hodes RJ, Lonser RR, Brady RO, Zhuang Z. Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl. Proc Natl Acad Sci U S A. 2010;107(50):21665-70.
58. Lieblich M, Altarescu G, Zimran A, Elstein D. Vitamin D Receptor (VDR) polymorphic variants in patients with cancer and Gaucher disease. Blood Cell Mole Dis. 2011;46:92-4.
59. Philip Stein, Clarence Zhang, Jun Liu, Gregory M Pastores, Zuoheng Wang, Ruhua Yang, Judy Cho, Peter Gregersen, Hongyu Zhao, Pramod K. Mistry. Genome-wide association study of N370S homozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing to extreme phenotypic variation in Gaucher disease. Am J Hematol. 2012. 87:377-83.
60. Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, Beutler E. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine. 1992;71:337-53.
61. Weinreb NJ, Cappellini MD, Cox TM, Giannini EH, Grabowski GA, Hwu WL, Mankin H, Martins AM, Sawyer C, vom Dahl S, Yeh MS, Zimran A. A validated disease severity scoring system for adults with type 1 Gaucher disease. Gen Med. 2010;12: 44-51.
62. Sidransky E. Gaucher disease and parkinsonism. Mole Gen Metab. 2005;84:302-4.
63. Fleshner PR, Aufses AH, Jr., Grabowski GA, Elias R. A 27-year experience with splenectomy for Gaucher's disease. Am J Surg. 1991;161:69-75.
64. Weinreb NJ, Deegan P, Kacena KA, Mistry P, Pastores GM, Velentgas P, vom Dahl S. Life expectancy in Gaucher disease type 1. Am J Hematol. 2008;83:896-900.
65. Mellemkjoer L, Olsen JH, Linet MS, Gridley G, McLaughlin JK. Cancer risk after splenectomy. Cancer. 1995;75:577-83.
66. Radin NS. Chemotherapy by slowing glucosphingolipid synthesis. Biochem Pharmacol. 1999;57:589-95.
67. Mistry PK, Weinreb NJ, Brady RO, Grabowski GA. Gaucher disease: resetting the clinical and scientific agenda. Am J Hematol. 2009;84:205-7.
68. Cox TM. Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. Curr Opin Investig Drugs. 2010;11:1169-81.
69. Lo SM, Choi M, Liu J, Jain D, Boot RG, Kallemeijn WW, Aerts JM, Pashankar F, Kupfer G, Mane S, Lifton RP, Mistry PK. (2012) Phenotypic diversity in type 1 Gaucher disease: Discovering the Genetic Basis of Gaucher disease/hematological malignancy phenotype by whole exome capture and massively parallel sequencing. Blood, 2012 May 17;119(20):4731-40.